Harrow, Inc. (HROW)

Harrow's stock price has been impacted by several events in the past six months. The company reported its Q2 2025 and Q3 2025 earnings. Following its Q3 2025 earnings release, HROW shares gained 13.5% the next day and have since drifted 41.5% higher. The stock price as of January 9, 2026, was $46.78, representing a 27.57% increase from January 10, 2025. The elevation of Harrow's dry eye treatment VEVYE to Tier 1 formulary status by CVS's pharmacy benefit manager in December 2025, is expected to significantly improve patient access and future prescription volumes. The company also announced strategic acquisitions, including Melt Pharmaceuticals, Inc. in November 2025, and a commercialization agreement with Samsung Bioepis for an ophthalmology biosimilars portfolio in the United States in July 2025.

Demand for Harrow, Inc.'s products and services exhibits a predictable seasonal pattern. The first quarter is typically the weakest financial quarter due to factors such as prior-quarter stocking by distributors, surgical scheduling patterns, and the resetting of annual insurance deductibles. The second quarter usually outperforms the first, and the second half of the year generally outperforms the first half, with the fourth quarter being the strongest due to increased year-end patient activity and distributor purchasing patterns.

Harrow, Inc. is an eyecare pharmaceutical company focused on the discovery, development, and commercialization of ophthalmic pharmaceutical products, operating within the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry. The company specializes in providing solutions for ophthalmic disease management in North America, offering a comprehensive portfolio of prescription and non-prescription pharmaceutical products. Key products and services include ImprimisRx, IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, NEVANAC, FLAREX, MAXIDEX, NATACYN, ZERVIATE, MAXITROL eye drops, TOBRADEX ST, VERKAZIA, FRESHKOTE, BYOOVIZ, and OPUVIZ.

Harrow, Inc. is headquartered in Nashville, Tennessee, United States. The company primarily operates across the United States and North America, with its pharmaceutical production and distribution facilities located in Ledgewood, New Jersey.

Harrow, Inc. aims to be a leading provider of ophthalmic disease management solutions, committed to delivering safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. The company has been actively expanding its market-leading ophthalmic business and was the first U.S. ophthalmic pharmaceutical company to offer both compounded and FDA-approved products. Recent positive developments, such as the successful launch and market access for VEVYE and strategic acquisitions, contribute positively to its brand reputation. However, in February 2023, the company faced scrutiny regarding an FDA Form 483 inspection report citing unsanitary conditions and drug quality issues, a subsequent nationwide recall, and a U.S. Department of Justice investigation into Dexycu sales practices.

Harrow, Inc. has 357 institutional owners and shareholders holding a total of 23,747,941 shares. Institutional ownership accounts for 51.56% of the company, while individuals hold 16.3%. Major institutional owners include Opaleye Management Inc., BlackRock, Inc., Vanguard Group Inc, Private Capital Management, LLC, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, State Street Corp, IWM - iShares Russell 2000 ETF, Geode Capital Management, Llc, Royce & Associates Lp, and Marshall Wace, Llp. Notable individual owners include Mark L. Baum (CEO) and Andrew R. Boll (CFO).